drugset / Trial / NCT01008917

Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

NCT01008917

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma. Temsirolimus is used to treat cancer in the kidneys. It is hoped that the addition of Temsirolimus will make Sorafenib more effective against Advanced Hepatocellular Carcinoma, however this can not be guaranteed. The addition of Temsirolimus to Sorafenib is not an FDA approved treatment for Advanced Hepatocellular cancer.

Timeline

Start
2009-11-17
Primary completion
2012-09-12
Completion
2013-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule Oral
Subject Temsirolimus Small molecule Intravenous